The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis

Journal of Lipid Research

Volumn 46, Issue 3, 2005, Pages 494-503

  Snyder, Peter B ^a   Esselstyn, James M ^a   Loughney, Kate ^a   Wolda, Sharon L ^a   Florio, Vincent A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Cilostamide; Rolipram; Triglyceride

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE INHIBITOR; CILOSTAMIDE; ESTERASE INHIBITOR; IC 224; IC 933; ISOBUTYLMETHYLXANTHINE; MILRINONE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE IV INHIBITOR; ROLIPRAM; SPLEEN EXONUCLEASE; UNCLASSIFIED DRUG; EXONUCLEASE; PHOSPHODIESTERASE IV;

ADIPOCYTE; ANIMAL CELL; ANIMAL CELL CULTURE; ARTICLE; CELL STIMULATION; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME REPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LIPOLYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; REGULATORY MECHANISM; ANIMAL; CELL CULTURE; CELL STRAIN 3T3; DOSE RESPONSE; DRUG ANTAGONISM; METABOLISM; PHYSIOLOGY;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; 3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; EXONUCLEASES; HUMANS; LIPOLYSIS; MICE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITORS; RATS;

EID: 24144491356     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M400362-JLR200     Document Type: Article

References (53)

1. Holm, C. 2003. Molecular mechanisms regulating hormone-sensitive lipase and lipolysis. Biochem. Soc. Trans. 31: 1120-1124.
2. Steinberg, D., and J. K. Huttunen. 1972. The role of cyclic AMP in activation of hormone-sensitive lipase of adipose tissue. Adv. Cyclic Nucleotide Res. 1: 47-62.
3. Osuga, J., S. Ishibashi, T. Oka, H. Yagyu, R. Tozawa, A. Fujimoto, F. Shionoiri, N. Yahagi, F. B. Kraemer, O. Tsutsumi, and N. Yamada. 2000. Targeted disruption of hormone-sensitive lipase results in male sterility and adipocyte hypertrophy, but not in obesity. Proc. Natl. Acad. Sci. USA. 97: 787-792.
4. Okazaki, H., J. Osuga, Y. Tamura, N. Yahagi, S. Tomita, F. Shionoiri, Y. Iizuka, K. Ohashi, K. Harada, S. Kimura, T. Gotoda, H. Shimano, N. Yamada, and S. Ishibashi. 2002. Lipolysis in the absence of hormone-sensitive lipase: evidence for a common mechanism regulating distinct lipases. Diabetes. 51: 3368-3375.
5. Haemmerle, G., R. Zimmermann, M. Hayn, C. Theussl, G. Waeg, E. Wagner, W. Sattler, T. M. Magin, E. F. Wagner, and R. Zechner. 2002. Hormone-sensitive lipase deficiency in mice causes diglyceride accumulation in adipose tissue, muscle, and testis. J. Biol. Chem. 277: 4806-4815.
6. Egan, J. J., A. S. Greenberg, M. K. Chang, S. A. Wek, M. C. Moos, Jr., and C. Londos. 1992. Mechanism of hormone-stimulated lipolysis in adipocytes: translocation of hormone-sensitive lipase to the lipid storage droplet. Proc. Natl. Acad. Sci. USA. 89: 8537-8541.
7. Londos, C., D. L. Brasaemle, C. J. Schultz, J. P. Segrest, and A. R. Kimmel. 1999. Perilipins, ADRP, and other proteins that associate with intracellular neutral lipid droplets in animal cells. Semin. Cell Dev. Biol. 10: 51-58.
8. Souza, S. C., L. M. de Vargas, M. T. Yamamoto, P. Lien, M. D. Franciosa, L. G. Moss, and A. S. Greenberg. 1998. Overexpression of perilipin A and B blocks the ability of tumor necrosis factor-α to increase lipolysis in 3T3-L1 adipocytes. J. Biol. Chem. 273: 24665-24669.
9. Tansey, J. T., A. M. Huml, R. Vogt, K. E. Davis, J. M. Jones, K. A. Fraser, D. L. Brasaemle, A. R. Kimmel, and C. Londos. 2003. Functional studies on native and mutated forms of perilipins. A role in protein kinase A-mediated lipolysis of triacylglycerols. J. Biol. Chem. 278: 8401-8406.
10. Clifford, G. M., C. Londos, F. B. Kraemer, R. G. Vernon, and S. J. Yeaman. 2000. Translocation of hormone-sensitive lipase and perilipin upon lipolytic stimulation of rat adipocytes. J. Biol. Chem. 275: 5011-5015.
11. Sztalryd, C., G. Xu, H. Dorward, J. T. Tansey, J. A. Contreras, A. R. Kimmel, and C. Londos. 2003. Perilipin A is essential for the translocation of hormone-sensitive lipase during lipolytic activation. J. Cell Biol. 161: 1093-1103.
12. Cohen, A. W., B. Razani, W. Schubert, T. M. Williams, X. B. Wang, P. Iyengar, D. L. Brasaemle, P. E. Scherer, and M. P. Lisanti. 2004. Role of caveolin-1 in the modulation of lipolysis and lipid droplet formation. Diabetes. 53: 1261-1270.
13. Cummings, D. E., E. P. Brandon, J. V. Planas, K. Motamed, R. L. Idzerda, and G. S. McKnight. 1996. Genetically lean mice result from targeted disruption of the RIIβ subunit of protein kinase A. Nature. 382: 622-626.
14. Francis, S. H., I. V. Turko, and J. D. Corbin. 2001. Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. 65: 1-52.
15. Schmitz-Peiffer, C., M. L. Reeves, and R. M. Denton. 1992. Characterization of the cyclic nucleotide phosphodiesterase isoenzymes present in rat epididymal fat cells. Cell. Signal. 4: 37-49.
16. Coudray, C., C. Charon, N. Komas, G. Mory, F. Diot-Dupuy, V. Manganiello, P. Ferre, and R. Bazin. 1999. Evidence for the presence of several phosphodiesterase isoforms in brown adipose tissue of Zucker rats: modulation of PDE2 by the fa gene expression. FEBS Lett. 456: 207-210.
17. Shakur, Y., K. Takeda, Y. Kenan, Z. X. Yu, G. Rena, D. Brandt, M. D. Houslay, E. Degerman, V. J. Ferrans, and V. C. Manganiello. 2000. Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J. Biol. Chem. 275: 38749-38761.
18. Reinhardt, R. R., E. Chin, J. Zhou, M. Taira, T. Murata, V. C. Manganiello, and C. A. Bondy. 1995. Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases. J. Clin. Invest. 95: 1528-1538.
19. MacKenzie, S. J., S. J. Yarwood, A. H. Peden, G. B. Bolger, R. G. Vernon, and M. D. Houslay. 1998. Stimulation of p70S6 kinase via a growth hormone-controlled phosphatidylinositol 3-kinase pathway leads to the activation of a PDE4A cyclic AMP-specific phosphodiesterase in 3T3-F442A preadipocytes. Proc. Natl. Acad. Sci. USA. 95: 3549-3554.
20. Rahn, T., L. Ronnstrand, M. J. Leroy, C. Wernstedt, H. Tornqvist, V. C. Manganiello, P. Belfrage, and E. Degerman. 1996. Identification of the site in the cGMP-inhibited phosphodiesterase phosphorylated in adipocytes in response to insulin and isoproterenol. J. Biol. Chem. 271: 11575-11580.
21. Wijkander, J., T. R. Landstrom, V. Manganiello, P. Belfrage, and E. Degerman. 1998. Insulin-induced phosphorylation and activation of phosphodiesterase 3B in rat adipocytes: possible role for protein kinase B but not mitogen-activated protein kinase or p70 S6 kinase. Endocrinology. 139: 219-227.
22. Kitamura, T., Y. Kitamura, S. Kuroda, Y. Hino, M. Ando, K. Kotani, H. Konishi, H. Matsuzaki, U. Kikkawa, W. Ogawa, and M. Kasuga. 1999. Insulin-induced phosphorylation and activation of cyclic nucleotide phosphodiesterase 3B by the serine-threonine kinase Akt. Mol. Cell. Biol. 19: 6286-6296.
23. Hagstrom-Toft, E., J. Bolinder, S. Eriksson, and P. Arner. 1995. Role of phosphodiesterase III in the antilipolytic effect of insulin in vivo. Diabetes. 44: 1170-1175.
24. Moberg, E., S. Enoksson, and E. Hagstrom-Toft. 1998. Importance of phosphodiesterase 3 for the lipolytic response in adipose tissue during insulin-induced hypoglycemia in normal man. Horm. Metab. Res. 30: 684-688.
25. Elks, M. L., and V. C. Manganiello. 1984. Selective effects of phosphodiesterase inhibitors on different phosphodiesterases, adenosine 3′,5′-monophosphate metabolism, and lipolysis in 3T3-L1 adipocytes. Endocrinology. 115: 1262-1268.
26. Dorigo, P., R. M. Gaion, S. Mazzetto, A. Marcomini, and I. Maragno. 1989. Amrinone potentiates catecholamine-induced lipolysis in fat cells. Biochem. Pharmacol. 38: 855-858.
27. Shechter, Y. 1984. Differential effects of two phosphodiesterase inhibitors on fat cell metabolism. Endocrinology. 115: 1787-1791.
28. Kather, H., and A. Scheurer. 1987. Effects of different phosphodiesterase inhibitors on the antilipolytic action of insulin in human adipocytes. Horm. Metab. Res. 19: 379-381.
29. Wilmshurst, P. T., D. S. Thompson, S. M. Juul, B. S. Jenkins, D. J. Coltart, and M. M. Webb-Peploe. 1984. Comparison of the effects of amrinone and sodium nitroprusside on haemodynamics, contractility, and myocardial metabolism in patients with cardiac failure due to coronary artery disease and dilated cardiomyopathy. Br. Heart J. 52: 38-48.
30. Ruttimann, Y., R. Chiolero, J. P. Revelly, N. Jeanpretre, and Y. Schutz. 1994. Thermogenic effect of amrinone in healthy men. Crit. Care Med. 22: 1235-1240.
31. Arner, P., J. Hellmer, E. Hagstrom-Toft, and J. Bolinder. 1993. Effect of phosphodiesterase inhibition with amrinone or theophylline on lipolysis and blood flow in human adipose tissue in vivo as measured with microdialysis. J. Lipid Res. 34: 1737-1743.
32. Snyder, P., S. Wolda, J. Esselstyn, K. Loughney, and V. Florio. 1999. Regulation of lipolysis in murine 3T3-L1 adipocytes by cAMP phosphodiesterases (Abstract). Obes. Res. 7 (Suppl.): 76.
33. m cyclic AMP phosphodiesterase (cGI PDE) in 3T3-L1 adipocytes. Biochem. Biophys. Res. Commun. 183: 1070-1075.
34. Negrel, R., and C. Dani. 2001. Culture of adipose precursor cells and cells of clonal lines from animal white adipose tissue. In Adipose Tissue Protocols. G. Ailhaud, editor. Humana Press, Inc., Totowa, NJ. 225-237.
35. Rubin, C. S., A. Hirsch, C. Fung, and O. M. Rosen. 1978. Development of hormone receptors and hormonal responsiveness in vitro. Insulin receptors and insulin sensitivity in the preadipocyte and adipocyte forms of 3T3-L1 cells. J. Biol. Chem. 253: 7570-7578.
36. Fredholm, B. B., and E. Lindgren. 1984. The effect of alkylxanthines and other phosphodiesterase inhibitors on adenosine-receptor mediated decrease in lipolysis and cyclic AMP accumulation in rat fat cells. Acta Pharmacol. Toxicol. 54: 64-71.
37. Ukena, D., C. Schudt, and G. W. Sybrecht. 1993. Adenosine receptor-blocking xanthines as inhibitors of phosphodiesterase isozymes. Biochem. Pharmacol. 45: 847-851.
38. 3- adrenoreceptor agonists as antiobesity and antidiabetic drugs in humans: current status and future prospects. Drug Dev. Res. 51: 80-93.
39. Pan, X., E. Arauz, J. J. Krzanowski, D. F. Fitzpatrick, and J. B. Polson. 1994. Synergistic interactions between selective pharmacological inhibitors of phosphodiesterase isozyme families PDE III and PDE IV to attenuate proliferation of rat vascular smooth muscle cells. Biochem. Pharmacol. 48: 827-835.
40. O'Grady, S. M., X. Jiang, P. J. Maniak, W. Birmachu, L. R. Scribner, B. Bulbulian, and G. W. Gullikson. 2002. Cyclic AMP-dependent Cl secretion is regulated by multiple phosphodiesterase subtypes in human colonic epithelial cells. J. Membr. Biol. 185: 137-144.
41. Lindgren, S., A. Rascon, K. E. Andersson, V. Manganiello, and E. Degerman. 1991. Selective inhibition of cGMP-inhibited and cGMP-noninhibited cyclic nucleotide phosphodiesterases and relaxation of rat aorta. Biochem. Pharmacol. 42: 545-552.
42. Komas, N., C. Lugnier, and J. C. Stoclet. 1991. Endothelium-dependent and -independent relaxation of the rat aorta by cyclic nucleotide phosphodiesterase inhibitors. Br. J. Pharmacol. 104: 495-503.
43. Rabe, K. F., H. Tenor, G. Dent, C. Schudt, S. Liebig, and H. Magnus-sen. 1993. Phosphodiesterase isozymes modulating inherent tone in human airways: identification and characterization. Am. J. Physiol. 264: L458-L464.
44. Inoue, Y., K. Toga, T. Sudo, K. Tachibana, S. Tochizawa, Y. Kimura, Y. Yoshida, and H. Hidaka. 2000. Suppression of arterial intimal hyperplasia by cilostamide, a cyclic nucleotide phosphodiesterase 3 inhibitor, in a rat balloon double-injury model. Br. J. Pharmacol. 130: 231-241.
45. Palmer, D., K. Tsoi, and D. H. Maurice. 1998. Synergistic inhibition of vascular smooth muscle cell migration by phosphodiesterase 3 and phosphodiesterase 4 inhibitors. Circ. Res. 82: 852-861.
46. Moon, E., R. Lee, R. Near, L. Weintraub, S. Wolda, and A. Lerner. 2002. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia. Clin. Cancer Res. 8: 589-595.
47. + T-lymphocytes: role in regulating proliferation and the biosynthesis of interleukin-2. Br. J. Pharmacol. 118: 1945-1958.
48. Essayan, D. M., A. Kagey-Sobotka, L. M. Lichtenstein, and S. K. Huang. 1997. Regulation of interleukin-13 by type 4 cyclic nucleotide phosphodiesterase (PDE) inhibitors in allergen-specific human T lymphocyte clones. Biochem. Pharmacol. 53: 1055-1060.
49. Gantner, F., S. Kusters, A. Wendel, A. Hatzelmann, C. Schudt, and G. Tiegs. 1997. Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. J. Pharmacol. Exp. Ther. 280: 53-60.
50. Flegal, K. M., M. D. Carroll, C. L. Ogden, and C. L. Johnson. 2002. Prevalence and trends in obesity among US adults, 1999-2000. J. Am. Med. Assoc. 288: 1723-1727.
51. Ogden, C. L., K. M. Flegal, M. D. Carroll, and C. L. Johnson. 2002. Prevalence and trends in overweight among US children and adolescents, 1999-2000. J. Am. Med. Assoc. 288: 1728-1732.
52. Yanovski, S. Z., and J. A. Yanovski. 2002. Obesity. N. Engl. J. Med. 346: 591-602.
53. Snyder, P. B. 1999. The adipocyte cGMP-inhibited cyclic nucleotide phosphodiesterase (PDE3B) as a target for lipolytic and thermogenic agents for the treatment of obesity. Emerging Therapeutic Targets. 3: 587-599.